Venturing into the Brave New World of Diagnostics Start-Ups

Few diagnostics start-ups are {bona fide} business successes, and that has put a damper on venture capital interest in the field. But this hasn't stopped start-ups trying to meet needs in cancer diagnostics, sample preparation and point-of-care.

Few diagnostics start-ups are bona fidebusiness successes, and that has put a damper on venture capital interest in the field. But it hasn't stopped some hearty pioneers from making bets on diagnostic tests. Perhaps they are attracted by the shorter time-to-market for diagnostics than pharmaceuticals or biotechnology, or the promise of a technology that meets an unmet need. Then again, diagnostics IPOs seem to garner attractive step-up multiples; a 5.2 pre-money average in 1997 and post-money average of 8.4, better than pharmaceutical companies' post-IPO multiple of 3.14 and 5.0 for device IPOs (including financings through August of ‘97), regardless of their eventual business success.(Step-up multiples calculate the increase in value from one financing round to the next by dividing pre-and post-money IPO valuations by total private investment.)

If investor interest is low, it isn't because the world has all the diagnostic tests it needs. And it isn't...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

Bristol Appoints AstraZeneca’s Massacesi As Next CMO

 

Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By 

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

More from Scrip

GSK’s Blenrep US Setback Could Go From Bad To Worse

 

With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.